John Maraganore, CEO of Alnylam Pharmaceuticals and current chair for BIO, shares thoughts on CROs, open science, and his company’s future.
The CEO and founder of Seattle Genetics, Clay Siegall, discusses one of the company’s new technologies, sugar-engineered antibodies (SEAs).
Print is not dead. In fact, Chief Editor Rob Wright believes we are on the verge of print’s resurgence, perhaps something similar to what’s being witnessed in the music industry with vinyl.
Clay Siegall, Ph.D., president, CEO, and chairman of Seattle Genetics, gives an exclusive interview about his company’s potential blockbuster, how they got to this point, and what’s next.
The founder and CEO of Seattle Genetics discusses a number of interesting topics, including how he was able to get the founders of Microsoft as early investors in his company.
Clay Siegall, the founder of Seattle Genetics, explains how his company became an unintentional-startup incubator for Alder BioPharmaceuticals.
The CEO of Seattle Genetics discusses the past, present, and future of some of his company’s partnerships.
How the 10 largest publicly traded biopharmaceutical companies compare to 10 of the largest publicly traded nonbiopharmaceutical companies in the area of gender diversity among executive leadership.
An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.
How can we address challenges that have plagued our past, such as egregious drug price increases, corruption, collusion, deception, and unethical marketing practices?
Successful drug discovery and development requires a passionate commitment, something that can only be displayed during the breakout sessions at the J.P. Morgan annual healthcare conference.
While some continue to focus on the lack of gender diversity at the annual J.P. Morgan healthcare conference, GSK’s CEO, Emma Walmsley, notes that supporting diversity means doing more than just focusing on the “gender agenda.”
The annual J.P. Morgan and Biotech Showcase conferences not only provide great networking opportunities, they expose you to interesting and cutting-edge companies to keep on your radar.
How long should a CEO stay in the job? Some experts say the best scenario for a CEO whose performance is declining is to get going while the going is still good. In other words, leave while they are at the peak of their performance, just before the decline.
Recounting what an executive did while on sabbatical wouldn’t normally fit into our editorial model. That is, unless that executive is Richard Bagger, J.D., EVP of corporate affairs and market access for Celgene.